PreludeDx Announces First Independent Validation of AidaBreastâ„¢, the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer
Newswise — LAGUNA HILLS, Calif., Dec. 10, 2025 — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for…